Updates for Pharmacists on BTK Inhibitors in Treating B-Cell Malignancies

B-cell malignancies have historically been treated with intravenous cytotoxic chemotherapies and immunotherapies, with treatment options now including oral therapies. Bruton’s tyrosine kinase (BTK) inhibitors are now recommended in the treatment paradigm of many B-cell malignancies, with clinical data and guidelines continually evolving. This program will review emerging data for the use of BTK inhibitors, as well as the role of digital technologies to assist in medication adherence and coordination of care. Additionally, adverse effect incidence and management strategies will be discussed, with an emphasis on bleeding and cardiac effects.

Target audience: Oncology pharmacists

Type of activity: Application

Release date: December 3, 2021

Expiration date: December 3, 2022

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate clinical evidence supporting the use of BTK inhibitors in B-cell malignancies
• Explore cardiac and bleeding risks associated with BTK inhibitors as well as strategies to improve patient outcomes
• Analyze potential advantages and strategies for implementing digital technologies in oncology care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-424-H01-P. The activity is available for CE credit through December 3, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Anthony J. Perissinotti, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms